Shortly after SARS-CoV emerged at the turn of the 21st century, the spike (S) protein
(particularly in its prefusion [native] conformation) was identified as the immunodominant …

Vaccine candidates based on spike, the glycoprotein that is essential for host cell entry by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were being designed …

The emergence of SARS-CoV-2 has resulted in> 90,000 infections and> 3,000 deaths.
Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged
coronavirus that is responsible for the current pandemic of coronavirus disease 2019 …

The SARS-CoV-2 spike (S) glycoprotein is synthesized as a large precursor protein and
must be activated by proteolytic cleavage into S1 and S2. A recombinant modified vaccinia …

The majority of SARS-CoV-2 vaccines in use or advanced development are based on the
viral spike protein (S) as their immunogen. S is present on virions as prefusion trimers in …

In this issue of JAMA, Zhang and colleagues1 report the emergence of a novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in Southern California that …

A recent paper published in Science describes the detection of IgG antibody responses in
individuals infected by severe acute respiratory syndrome coronavirus (SARS-CoV-2). The …

One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …

Developing therapeutics against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) could be guided by the distribution of epitopes, not only on the receptor binding …